DelveInsight’s, “Dyskinesia Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in the Dyskinesia pipeline landscape. It covers the Dyskinesia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dyskinesia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Dyskinesia Pipeline Report

• DelveInsight’s Dyskinesia pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Dyskinesia treatment.
• The leading companies working in the Dyskinesia Market include Contera Pharma, VistaGen Therapeutics Inc., Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, PharmaTher, Integrative Research Laboratories AB, Teva Branded Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences Inc., PolyCore, SOM Biotech, and others.
• Promising Dyskinesia Pipeline Therapies in the various stages of development include JM-010 group A, VX-371, Hypertonic Saline, NLX-112, SD-809, MT-5199, Valbenazine, NBI-98854, and others.
• August 2023: Intra-Cellular Therapeutics Inc. announced a study of phase 2 clinical trials for Lenrispodun. This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson’s Disease consistent with the UK Parkinson’s Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
• September 2023: Teva Branded Pharmaceutical Products R&D Inc. announced a study of phase 3 clinical trials for TEV-50717. This is a Phase 3 study that will evaluate the efficacy and safety of TEV-50717 administered as oral tablets at a starting dose of 6 mg once daily in participants (age 6 through 18 years, inclusive) with DCP with predominant choreiform movement disorder. The study will be conducted in multiple centers and will use 2 parallel treatment groups (ie, TEV-50717 and placebo) in which participants will be randomized in a 2:1 ratio.

 

Request a sample and discover the recent advances in Dyskinesia Treatment Drugs @ Dyskinesia Pipeline Report

 

In the Dyskinesia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dyskinesia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Dyskinesia Overview

Dyskinesia’s are involuntary, erratic, writhing movements of the face, arms, legs or trunk. They are often fluid and dance-like, but they may also cause rapid jerking or slow and extended muscle spasms. They are not a symptom of Parkinson’s itself. Rather, they are a complication from some Parkinson’s medications.

 

Find out more about Dyskinesia Therapeutics Assessment @ Dyskinesia Preclinical and Discovery Stage Products

 

Dyskinesia Emerging Drugs Profile

• JM-010: Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma

 

Dyskinesia Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Dyskinesia therapies. The Dyskinesia companies which have their Dyskinesia drug candidates in the most advanced stage, i.e. phase II include, Contera Pharma.

 

Learn more about the emerging Dyskinesia Pipeline Therapies @ Dyskinesia Clinical Trials Assessment

 

Scope of the Dyskinesia Pipeline Report

• Coverage- Global
• Dyskinesia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dyskinesia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Dyskinesia Companies- Contera Pharma, VistaGen Therapeutics Inc., Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, PharmaTher, Integrative Research Laboratories AB, Teva Branded Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences Inc., PolyCore, SOM Biotech, and others.
• Dyskinesia Pipeline Therapies- JM-010 group A, VX-371, Hypertonic Saline, NLX-112, SD-809, MT-5199, Valbenazine, NBI-98854, and others.

 

Dive deep into rich insights for new drugs for Dyskinesia Treatment, Visit @ Dyskinesia Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Dyskinesia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dyskinesia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. JM-010: Contera Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name : Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dyskinesia Key Companies
21. Dyskinesia Key Products
22. Dyskinesia- Unmet Needs
23. Dyskinesia- Market Drivers and Barriers
24. Dyskinesia- Future Perspectives and Conclusion
25. Dyskinesia Analyst Views
26. Dyskinesia Key Companies
27. Appendix

 

For further information on the Dyskinesia Pipeline therapeutics, reach out to Dyskinesia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking